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Understanding patient preferences will help physicians to manage their patients’ 
disease most effectively and potentially ensure greater adherence to therapy. 
Further research is warranted to understand patient preferences quantitatively.
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Objectives: To quantify UK psoriasis patients’ tolerance for serious side-effect 
risks associated with biologic treatments relative to the value of symptom improve-
ments. MethOds: Members of a UK psoriasis patient organization were invited to 
complete an on-line conjoint-analysis survey which evaluated efficacy and safety 
features of biologic treatments for psoriasis. Patients’ trade-off preferences for 
improvements in the severity and coverage of psoriatic lesions were elicited, as well 
as treatment-related risks of tuberculosis (TB), serious infections, and lymphoma. 
The choice pattern observed in the data was used to estimate preference weights 
which indicated patients’ relative trade-off preferences among treatment outcomes.
Preference weights were used to derive maximum levels of side-effect risks that 
patients would accept for various improvements in psoriasis symptoms. The DLQI 
was used to assess the impact of psoriasis on patients’ quality of life. Results: A 
total of 159 people with a self-reported physician diagnosis of psoriasis completed 
the survey. Mean age was 39 years and most respondents reported having psoriasis 
for at least 5 years. Also, the mean DLQI score was 11. Respondents would accept up 
to 0.39% of treatment-related risks of lymphoma for reducing the area covered by a 
severe lesion from 25% to 10% of their torso, and up to 0.60% if lesions were on their 
arms or legs.For the same improvement in symptoms, respondents would accept up 
to a 2.3% risk of TB or 3.3% risk of serious infections if the lesions were on their torso, 
and a 3.6% risk of TB or 5.2% risk of serious infections if the lesions were on their arms 
and legs. cOnclusiOns: Psoriasis patients’ tolerance for side-effect risks varies with 
side-effect severity and location of lesions. Estimates of patients’ risk tolerance for 
serious side-effects indicate that patients value psoriasis symptom control further 
confirming that psoriasis has a significant effect on patients’ quality of life.
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Objectives: Atopic Dermatitis (AD) is a common skin condition, even in adults. 
On the contrary of quality of life questionnaires, the notion of individual burden 
associated with a disease has been introduced to determine the “disability” in 
the broadest sense. The aim of the current study was to develop and validate 
the Atopic dermatitis Burden Scale questionnaire for Adults (ABS-A) following 
Classical Test Theory method (CTT). MethOds: The questionnaire was developed 
by a working group composed of individuals with expertise in PRO development, 
dermatologists, and patients from patients’ association. Subsequently, this ques-
tionnaire was sent to 900 people with AD. ABS-A was refined via exploratory factor 
analysis (EFA). Internal consistency was determined by calculating the Cronbach’s 
alpha, concurrent validity by calculating the Spearman’s rank coefficient correla-
tion between ABS-A, SF-12 and Dermatology Life Quality Index (DLQI) question-
naires. Discriminant validity was analysed according to the severity degrees of AD 
assessed by the Patient Oriented SCORing index of AD questionnaire. Results: 
A total of 128 individuals filled out the ABS-A entirely and were then evaluated. 
68.8% of them were men and almost 50% of them were aged between 35 and 64 
years old. Based on the results of the EFA, 1 item was removed due to cross-loading 
on factors. Consequently, the questionnaire consisted of 18 items grouped into 
4 domains. ABS-A showed good internal coherence (Cronbach’s á: 0.89). ABS was 
significantly correlated to both components of the SF-12 (r(PCS)= -0.36, p< 0.0001; 
r(MCS)= -0.52 , p< 0.0001). A higher coefficient correlation has been found between 
ABS-A and DLQI (r= 0.78; p< 0.0001). Significant differences between severity 
degrees of AD have been shown. cOnclusiOns: These preliminary results 
suggest the validity of the ABS-A questionnaire. However, since recruitment of 
patients is not achieved, performing analyses of the other stages of CTT, and 
Confirmatory Factor analysis or Rash analysis are warranted. Comparison between 
both methods may be valuable.
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Objectives: The notion of individual burden, associated with the disease, has been 
introduced recently to determine the “disability” caused by the pathology in the 
broadest sense of the word (psychological-social-economic-physical). MethOds: 
The ABS questionnaire (Atopy Burden Score Q) consists of 19 items, structured 
around 5 components. It was distributed to a random sample of families consulting 
at the Necker Hospital, staying at the Avène Hydrotherapy Center, and members of 
the patient-association. The ABS was accompanied by SF12 and PGWBI, to confirm 
internal and external validation, and by the PO-SCORAD to assess the level of sever-
ity. Results: A total of 58 Q were considered evaluable. 51% of the AD children 
were girls. The PO-SCORAD established the level of severity of the AD: 14%, 50% and 
36% of children had mild, moderate or severe AD respectively. Internal-validity was 
measured by Cronbach’s alpha, which is equal to 0.81, reflecting a good homogeneity 
of the 19 items. The mean PGWBI score is 51.82±14.28. The score reflecting the most 
important deterioration is found among parents of children with severe atopy. In 
contrast, the scores associated with moderate and mild atopy are not correlated 
with severity. Families’ QoL, measured using the SF12, revealed no deterioration 
in the physical component. The ABS score is correlated with the scores of the Q 
little difference. cOnclusiOns: Using a sequence model of biologic therapies in 
psoriasis, first-line ustekinumab was found to be cost-effective in the treatment 
of moderate-to-severe psoriasis in Finland.
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Objectives: To calculate the Cost-Utility of unilateral pediatric Cochlear Implantation 
in Hungary. Parallel to that, we aim to provide an assessment of currently served cases 
and epidemiological demand. MethOds: Cost accounting of direct medical costs, 
from public purchaser perspective, covering medical resources sacrificed for unilateral 
implant in 1 year children, with a 60 year life expectancy. Cost-utility is calculated 
based on direct costs and QALY gain retrieved from literature, both to be discounted 
at 3% annually. Prevalence of eligible newborns to undergo Cochlear Implantation 
versus served cases is reported. Results: Draft estimation of total direct costs is 
12.26 million HUF (25,288 EUR) and when discounted it would be 7.3 million HUF 
(24,219 EUR). This is divided into 2.1% preoperative, 53.8% operative (including cost 
of implant) and 44% post operative. Based on health utility reported by Cheng, dis-
counted QALY gain ranges from 6.1 to 10.8 life years. Therefore, Cost-utility of uni-
lateral CI would range from 679,433 HUF (2,343 EUR) to 1,204,449 HUF (4,153 EUR) per 
discounted QALY gain. Currently in Hungary, about 90 cases are operated per year 
(0.1 % of crude birth rate). From 220 to 250 new cases, 2.5 to 3 times currently served, 
every year (0.24 – 0.37 % of crude birth rate), would be necessary for providing equal 
access to care. cOnclusiOns: This study provides an overview to Hungarian policy 
makers and other stakeholders about cost-utility, direct costs and estimated effect, 
and also of the possible full capacity of such costly intervention. Unilateral Cochlear 
Implantation appears to be reasonable if direct costs per QALY are compared to GDP 
in Hungary. Hungarian values are compared with international values.
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Objectives: Psoriasis is a chronic, systemic immune-mediated disorder char-
acterised by skin and often joint involvement affecting 2.3% of the Australian 
population. While psoriasis has traditionally been viewed as a non-serious skin 
condition, it is now recognised as a systemic inflammatory disease with a growing 
body of evidence linking the condition with a number of serious co-morbidities. 
The objective of this study was to determine the burden, in terms of disutility and 
resource use, that co-morbidities have on patients with psoriasis. MethOds: A 
large-scale, multi-centre, cross-sectional study of Australian adults with psoria-
sis was conducted during 2011. The survey contained 43 questions and focused 
primarily on comorbidity, health care resource use and the impact of psoriasis 
on disutility as assessed by EQ-5D. Results: A total of 330 patients responded 
to the survey. Three-quarters of respondents reported having at least two or 
more concomitant medical conditions, with only 8% reporting no comorbidities. 
Combined, joint-related conditions such as joint pain (46%) and psoriatic arthritis 
(28%) represented the largest proportion of medical comorbidities reported. The 
mean EQ-5D score for the cohort was 0.73. Utility decreased as the number of co-
morbidities increased, ranging from 0.88 for patients with no co-morbidities to 
0.36 for patients with 9 co-morbidities. Resource use and out of pocket expenses 
also increased with increasing number of co-morbidities. cOnclusiOns: This 
study highlights the co-morbid nature of psoriasis with most respondents report-
ing having two or more concomitant conditions. Furthermore, based on the mean 
EQ-5D health status score, psoriasis has a considerable impact on patient quality 
of life comparable with other chronic diseases.
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Objectives: To investigate qualitatively patient preferences for monitoring and 
treatment in the management of neovascular (wet) age-related macular degen-
eration (wAMD) in different countries. MethOds: The study involved 39 patients 
with wAMD from the UK (n= 9), Canada (n= 10), Germany (n= 10) and Japan (n= 10). 
Subjects participated in a 30-minute semi-structured telephone interview. Data 
were analysed to identify key themes and opinions. Results: Most (74%, n= 29) 
patients were aged ≥ 70 years, 28% (n= 11) required a caregiver to attend clinic visits, 
and 90% (n= 35) had comorbidities. Only 13% (n= 5) of patients were treatment-
naïve, 41% (n= 16) had received ≤ 1 year of therapy and 46% (n= 18) had received > 
1 year of therapy. Most (92%, n= 36) were currently or had previously been receiving 
ranibizumab; 8% (n= 3) were receiving or about to initiate therapy with aflibercept. 
Most patients (62%, n= 24) preferred monthly monitoring with treatment given as 
needed based on disease progression, 26% (n= 10) preferred bimonthly monitoring 
and fixed bimonthly dosing and 13% (n= 5) had no preference. Patients reported 
being very anxious about their sight and tended implicitly to trust their treat-
ing physician to decide on the most appropriate treatment; as a result, patients 
reported being highly adherent to therapy. Many patients reported appreciating 
the reassurance provided by frequent monitoring and were very satisfied with 
their current dosing regimen as chosen by their treating physician. cOnclusiOns: 
The results of this pilot, qualitative study suggest that most patients prefer 
frequent monitoring with dosing based on disease progression to treat their wAMD. 
